Money Friday, June 24, 2011
FORTUNE — Big pharmaceutical companies aren’t at a crossroads so much as on the edge of a cliff. Thanks to a special provision in patent laws for drugs, companies lose intellectual property protection on pharmaceuticals after 20 years. After that, exclusive rights to the drugs fall into an abyss of competition from other companies making much cheaper generic versions. The point at which pharma companies lose exclusive rights to their drugs is called the patent cliff.
Yet one company, Allergan (AGN, Fortune 500), has managed to steer clear of the edge. Most big, mainstream pharma companies are desperately working to develop new expensive drugs and filing lawsuits to extend patents on old ones. But to dodge that deadline, Allergan is using another strategy; let’s call it the “stay small and make weird products” approach.
The company behind Botox®, the “face-lift in a bottle,” is itself aging rather gracefully. Net sales increased by 13.3%, to roughly $1.3 billion, in the first quarter of 2011 compared with the same period last year, and the company has given analysts no reason to think it won’t put together a string of good quarters.
https://www.facialesthetics.org/blog/allergans_survival_strategy_botox_everlasting
By Sydney Gatta, RN In the realm of facial aesthetics and rejuvenation, innovative treatments continue to emerge, offering patients a plethora of options to
By Arianna Bankovich, RN Introduction: Botox, derived from the bacterium Clostridium botulinum, has long been renowned for its cosmetic applications in reducing wrinkles and fine
By Crystal Wilson, CNP In the dynamic landscape of healthcare, career trajectories often take unexpected turns. One noticeable trend in recent years is the increasing